Palo Santo is a venture capital fund focused on backing emerging psychedelic therapeutics and neuroscience companies developing breakthrough treatments for mental health and central nervous system disorders. Founded in 2020, the firm is based in Chicago and closed its flagship fund at $50 million in 2022.
57% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $40.8M (across 11 rounds with reported amounts).
Portfolio
12
Fund Size
$50M
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Reunion Neuroscience | Series A | $103M | May 2024 |
 Psy Therapeutics | Unknown | $12.6M | Jan 2024 |
 Journey Clinical | Series A | — | Jan 2023 |
 Gilgamesh | Series B | $39M | Dec 2022 |
 Sensorium Therapeutics | Series A | $30M | Nov 2022 |
 Wavepaths | Seed | $4.5M | Nov 2021 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| Journey Clinical | Seed | $3M | Sep 2021 |
 Beckley Psytech | Series B | — | Aug 2021 |
 Ksana Health | Seed | $2M | Jun 2021 |
| Beckley Psytech | Series B | — | Jan 2021 |
 Syndeio Biosciences | Unknown | $90M | — |
 Psylo | Seed | $5M | — |
| SSyndeio | Unknown | $90M | — |
Top Co-Investors
Gaingels3 shared
PsyMed Ventures3 shared
Vanedge Capital3 shared
Prime Movers Lab3 shared
re.Mind Capital3 shared
Tenmile3 shared
Solari Capital2 shared
Fifty Years2 shared
Able Partners2 shared
Route 66 Ventures2 shared
Adage Capital Management2 shared
Integrated2 shared
FJ Labs2 shared
Catalio Capital Management2 shared
AbbVie2 shared
ARCH Venture Partners2 shared
Eli Lilly and Company2 shared
Union Square Ventures1 shared
Coalition Operators1 shared
Mosaic Ventures1 shared
Last updated: 7 October 2026